CHRONIC MYELOID LEUKEMIA (CML), as the name implies, is a chronic or slow-growing progression of a disease of myeloid cells (a type of White blood cells that become mature red blood cells, white blood cells, and platelets). In chronic myeloid leukemia, the bone marrow produces too many myeloid blood cells which are at various maturation stages including cells known as immature granulocytes, metamyelocytes, and myeloblasts.
The common chronic myeloid leukemia symptoms are-
CML is usually diagnosed in the 5th – 6th decade worldwide but in India, where it forms nearly 40-50 % of all Leukemias, it is diagnosed a decade earlier.
In 95 % of patients, there is swapping between a part of chromosomes number 9 and 22 which is also called TRANSLOCATION – t(9:22). This results in the production of a product called bcr-abl which results in impaired maturation and prevents cell death and enhances expansion of abnormal clone.
The following tests help in diagnosis –
Chronic myeloid leukemia stages are:
The first-line treatment of CML in most situations is oral medication. These pills have transformed the way we treat CML and have enabled a CML patient to lead a life like any other individual.
Generations of these drugs-
Imatinib was the first in a class of targeted therapies in cancer and it unleashed the era of precision medicine in cancer. 90% of patients initially started on Imatinib survived for nearly a decade during Follow up.
Regular Monitoring of the bcr-abl Transcript is required during the course of treatment and is possible by a simple blood test also called RQ-PCR.
Upon development of resistance to first-line treatment again precision medicine is used to point out the new aberrant mutation and the drug is chosen as per sensitivity.
Patients attaining deep response and durable ones lasting for nearly more than 2 years can also be considered for holding treatment but also require more intensive monitoring thereafter.
In Blast phase and accelerated phase, these oral medications are used as a bridge to allogeneic transplant in eligible patients.
Treatment should not be changed for patients who are asymptomatic and do not have documented infection with SARS-Cov-2. There is no increased Immunosuppression with the current use of TKI. There are pulmonary side effects associated with some TKIs, such as pleural effusion and pulmonary arterial hypertension, most common with dasatinib, which in theory might complicate or add to morbidity from severe SARS-CoV-2 infection. These adverse events should be managed as per standard practice.
HOD- Medical Oncology
Mucormycosis, popularly termed “Black fungus” by the media and public, is a disease…
The first wave of COVID-19 majorly affects people with advanced age and underlying…
In the year 1976, Dr Robert Brown and nurse Margaret Piehl had co-authored a paper.…